Genmab — Maj 2016
-
Well, we will see. No one knows, we can of course only make educated guesses. I have a increasing feeling that Gilead might surprise with a major deal on a completely unexpected target or for a surprising disease area outside the scope of Genmab's regular comfort zone. I take notice of the collaboration with Novo and the recent progress in the collaboration with Lundbeck
to support this view -
I think that Jan van der Winkel has been cited several times for stating that prolonged research sniffing remains in the interest of the shareholders as the price of a deal increases along with the time spent evaluating the potential. This gives us the right to have absolutely massive expectations with regards to Gilead
-
We have listened to many promises and much talk of world-class platforms, but we still miss to see tangible hard evidence that extends beyond Janssen and Gilead would be that magic silver bullet for Winkel. He has thus locked himself in a position where he needs to deliver. There is quite simply not room for any mediocre commercial deal with a major player
-
So, yes I expect a commercial deal on either Duobody, Hexabody or both in conjunction to be disruptive. If not, then I must honestly say that Mr Winkel has failed to deliver on his promise
-
I'm not forgetting Novartis. But, you are indeed referring solely to the idea of a looming takeover when you are bringing them to the table as an argument. I'm currently in the mixed terrain for talking about both deals/and or takeover..
-
Selv tak. Logger desværre af nu, sidder i et tog og er fremme ved destinationen
-
Men når vi får prominent besøg fra udlandet så må vi sørge for at tage os godt af dem..
-
You are all welcome and thanks to everyone for keeping this forum so god damn interesting to follow on a daily basis.. My advice to any English speakers.. Use google translate.. you will find an absolute treasure trove with information hidden here..
-
Selv tak David. Forsat god weekend.
-
Genmab berettiget til potentielle milepælsbetalinger på 250 mio. dollar for hver eksklusive licens eller cirka 200 mio. dollar for hver ikke-eksklusive licens. Derudover kommer royalties fra salg af eventuelle kommercielle produkter. http://borsen.dk/nyheder/virksomheder/artikel/1/308999/genmab_indgaar_stort_samarbejde_med_novo.html
-
Er der et link til det hele (lidt mere samlet) fra RIO ?
-
-
Mere opkøbs snak fra 2015: http://www.proinvestor.com/boards/72767/Genmab-som-opkoebsemne-eller-ej
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind